Sonnet BioTherapeutics Holdings, Inc.

SONN

US83548R3030

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 02:00:01 16/07/2024 am IST			5-day change	1st Jan Change
0.89 ^USD	+2.12%		-1.11%	-48.85%

05/07	Sonnet BioTherapeutics Files Registration for Sale of Up to 5.77 Million Shares by Selling Stockholders	MT
20/06	Top Midday Decliners	MT

Sonnet BioTherapeutics Shares Up 8% on Roche Collaboration

January 09, 2023 at 11:55 pm IST

By Josh Beckerman

Shares of Sonnet BioTherapeutics Holdings Inc. were up 8% to $1.40 after it announced a clinical collaboration agreement with Roche Holding AG.

In Sonnet's first combination clinical study, Sonnet's SON-1010 and Roche's atezolizumab will be evaluated in patients with platinum-resistant ovarian cancer.

Sonnet expects to begin the study in the second quarter.

In October, Sonnet announced a collaboration agreement with Janssen Biotech Inc., which is part of Johnson & Johnson. It said SON-1010, SON-1210 and SON-1410 would be evaluated in combination with certain Janssen proprietary cell therapy assets.

Write to Josh Beckerman at josh.beckerman@wsj.com

(END) Dow Jones Newswires

01-09-23 1325ET

Stocks mentioned in the article

	Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Price	Change	5d. change	Capi.
	ROCHE HOLDING AG	258 CHF	-0.29%	+5.44%	23TCr
	SONNET BIOTHERAPEUTICS HOLDINGS, INC.	0.89 USD	+2.12%	-1.11%	46.44L

Latest news about Sonnet BioTherapeutics Holdings, Inc.

Sonnet BioTherapeutics Files Registration for Sale of Up to 5.77 Million Shares by Selling Stockholders	06/07	MT
Top Midday Decliners	20/06	MT
Sonnet BioTherapeutics Holdings, Inc. Announces the Generation and Characterization of Two Novel Immunotherapeutic Pipeline Drug Candidates, SON-1411 and SON-1400, Each Containing a Variant IL-18 Domain	13/06	CI
Sonnet Biotherapeutics Holdings, Inc. to Present SB221 as A Trial in Progress At the Asco 2024 Annual Meeting	28/05	CI
Sonnet BioTherapeutics Holdings, Inc. Announces Review of Strategic Alternatives	22/05	CI
Sonnet BioTherapeutics Holdings, Inc. Announces Updated Clinical Data for Son-1010 as Monotherapy or Combined with an Anti-Pd-L1, Along with an Increase in the Dose-Escalation Target	20/05	CI
Sonnet BioTherapeutics Holdings, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2024	15/05	CI
Traders Anticipate Inflation Report as US Equities Open Lower on Wall Street	11/03	MT
Top Premarket Gainers	11/03	MT
Sonnet BioTherapeutics Holdings, Inc. Announces First Phase 1b/2a Clinical Trial of SON-080	11/03	CI
Chardan Cuts PT on Sonnet BioTherapeutics to $30 From $75 to Reflect Higher Projected Future Share Count, Keeps Buy Rating	15/02	MT
Sonnet BioTherapeutics Holdings, Inc. Reports Earnings Results for the First Quarter Ended December 31, 2023	14/02	CI
North American Morning Briefing : Stock Futures -2-	09/02	DJ
North American Morning Briefing : S&P 500 Futures Dip with Fresh Record in Sight	20/12	DJ
Sonnet BioTherapeutics Holdings, Inc. Reports Earnings Results for the Full Year Ended September 30, 2023	15/12	CI
North American Morning Briefing : Traders Await -2-	13/12	DJ
Ladenburg Thalmann Starts Sonnet BioTherapeutics Holdings With Buy Rating, $7 Price Target	27/11	MT
Sector Update: Health Care Stocks Retreating Late Afternoon	26/23/26	MT
Top Midday Decliners	25/23/25	MT
Top Premarket Decliners	25/23/25	MT
Sector Update: Health Care Stocks Lower in Late Afternoon Trading	01/23/01	MT
Sector Update: Health Care Stocks Lower Thursday Afternoon	31/23/31	MT
Sonnet BioTherapeutics to Implement 1-for-22 Reverse Stock Split; Shares Fall	31/23/31	MT
EF Hutton Assumes Sonnet BioTherapeutics at Buy With $6.70 Price Target	23/23/23	MT
Sector Update: Health Care Stocks Decreasing Late Afternoon	17/23/17	MT

Chart Sonnet BioTherapeutics Holdings, Inc.

Duration

Period

Chart Sonnet BioTherapeutics Holdings, Inc.

More charts

Company Profile

Sonnet BioTherapeutics Holdings, Inc. is a clinical-stage, oncology-focused biotechnology company. The Company's technology, namely Fully Human Albumin Binding (FHAB), utilizes a fully human single chain antibody fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. The Company designed the FHAB construct to improve drug accumulation in cancer tumors, as well as to extend the duration of activity in the body. Its lead asset, SON-1010, is a fully human single-chain version of Interleukin 12 (IL-12), covalently linked to the FHAB construct, for which it is pursuing clinical development in solid tumors. Its lead clinical-stage asset, SON-080, is a fully human version of IL-6 manufactured in Chinese Hamster Ovary (CHO) cells. SON-080, for its target indications of Chemotherapy-Induced Peripheral Neuropathy (CIPN) and Diabetic Peripheral Neuropathy (DPN). Its pipeline also includes SON-1210, SON-1410 and SON-3015.

Sector

Pharmaceuticals

Calendar

12/08/2024 - Q3 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.89 USD

Average target price

13 USD

Spread / Average Target

+1,360.67%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
SONNET BIOTHERAPEUTICS HOLDINGS, INC.	-48.85%	46.44L
ELI LILLY AND COMPANY	+63.05%	86TCr
NOVO NORDISK A/S	+39.98%	63TCr
JOHNSON & JOHNSON	-4.78%	36TCr
MERCK & CO., INC.	+17.52%	32TCr
ABBVIE INC.	+8.43%	30TCr
ROCHE HOLDING AG	+5.48%	23TCr
NOVARTIS AG	+16.51%	23TCr
AMGEN INC.	+14.63%	18TCr
PFIZER, INC.	+1.08%	16TCr

Other Pharmaceuticals

Sonnet BioTherapeutics Holdings, Inc.

Equities

SONN

US83548R3030

Pharmaceuticals

Sonnet BioTherapeutics Shares Up 8% on Roche Collaboration

Stocks mentioned in the article

Latest news about Sonnet BioTherapeutics Holdings, Inc.

Chart Sonnet BioTherapeutics Holdings, Inc.

Company Profile

Income Statement Evolution

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Pharmaceuticals